Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 1/20 | 0.43 |
| ▸ | MAOB | P27338 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.38 |
| ▸ | CA1 | P00915 | 9/20 | 0.36 |
| ▸ | CA2 | P00918 | 9/20 | 0.36 |
| ▸ | CA12 | O43570 | 3/20 | 0.36 |
| ▸ | CA9 | Q16790 | 3/20 | 0.36 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.36 |
| ▸ | MALT1 | Q9UDY8 | 1/20 | 0.34 |
| ▸ | ATM | Q13315 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
| ▸ | IDO1 | P14902 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15512334 | 1.00 | MAOA (0.43) | MAOAMAOBMEN1KMT2AGAA | |
| SCHEMBL15512396 | 0.87 | MAOA (0.45) | MAOAMAOBMEN1KMT2AGAA | |
| SCHEMBL27334263 | 0.76 | MEN1 (0.47) | MAOAMAOBMEN1KMT2AGAA | |
| SCHEMBL30841301 | 0.76 | MEN1 (0.47) | MAOAMAOBMEN1KMT2AGAA | |
| SCHEMBL14030599 | 0.74 | MAOA (0.48) | MAOAMAOBMEN1KMT2AGAA | |
| SCHEMBL608970 | 0.74 | MAOA (0.60) | MAOAMAOBMEN1KMT2AGAA | |
| SCHEMBL31365878 | 0.73 | CAPN1 (0.40) | MAOAMAOBMEN1KMT2AGAA | |
| SCHEMBL6555625 | 0.73 | ALOX15 (0.44) | KMT2A | |
| SCHEMBL19190339 | 0.73 | MEN1 (0.51) | MAOAMAOBMEN1KMT2AGAA | |
| SCHEMBL4967290 | 0.72 | MAOA (0.68) | MAOAMAOBMEN1KMT2AGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150133364-A1 | DIPEPTOID PRODRUGS AND THEIR USE | BAYER IP GMBH (DE) | 2015-05-14 | — | — | US | disclosed |
| US-8957017-B2 | Dipeptoid prodrugs and their use | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-02-17 | — | — | US | disclosed |
| US-20140206879-A1 | DIPEPTOID PRODRUGS AND THEIR USE | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-07-24 | — | — | US | disclosed |
| US-8703696-B2 | Dipeptoid prodrugs and the use thereof | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-04-22 | — | — | US | disclosed |
| EP-2185552-B1 | DIPEPTOID PRODRUGS AND THE USE THEREOF | BAYER IP GMBH (DE) | 2014-03-12 | — | — | EP | disclosed |
| US-20110294718-A1 | DIPEPTOID PRODRUGS AND THE USE THEREOF | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT | 2011-12-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140206879-A1 | DIPEPTOID PRODRUGS AND THEIR USE | DPP4, DPP3, DPP7 | MAOA 2413/4885MAOB 1835/4885MEN1 2264/4885 |
| US-20110294718-A1 | DIPEPTOID PRODRUGS AND THE USE THEREOF | DPP4, DPP3, DPP7 | MAOA 2379/4885MAOB 1669/4885MEN1 2035/4885 |
| US-20150133364-A1 | DIPEPTOID PRODRUGS AND THEIR USE | DPP4, DPP3, DPP7 | MAOA 2413/4885MAOB 1835/4885MEN1 2264/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.